TrovaGene, Inc. (NASDAQ:TROV)

CAPS Rating: 4 out of 5

Results 1 - 3 of 3

Recs

0
Member Avatar Aquest (66.27) Submitted: 2/18/2015 4:46:37 PM : Outperform Start Price: $5.00 TROV Score: +41.75

TROV is developing a method of detecting cancer through urinalysis. This has huge potential. Their tests will also help in determining how cancer treatments are working. All this while being non-invasive.

Recs

0
Member Avatar nancytroi (< 20) Submitted: 10/7/2013 11:40:15 AM : Outperform Start Price: $7.39 TROV Score: -27.60

New Diagnostic tests for cancer.

Recs

0
Member Avatar ctcarrigan33 (47.34) Submitted: 7/23/2013 12:14:52 PM : Outperform Start Price: $8.42 TROV Score: -38.39

Cheaper than blood tests or traditional tests, and their validation tests of the technology have been positive thus far

Results 1 - 3 of 3

Featured Broker Partners


Advertisement